metronidazole has been researched along with Esophageal Neoplasms in 14 studies
Metronidazole: A nitroimidazole used to treat AMEBIASIS; VAGINITIS; TRICHOMONAS INFECTIONS; GIARDIASIS; ANAEROBIC BACTERIA; and TREPONEMAL INFECTIONS.
metronidazole : A member of the class of imidazoles substituted at C-1, -2 and -5 with 2-hydroxyethyl, nitro and methyl groups respectively. It has activity against anaerobic bacteria and protozoa, and has a radiosensitising effect on hypoxic tumour cells. It may be given by mouth in tablets, or as the benzoate in an oral suspension. The hydrochloride salt can be used in intravenous infusions. Metronidazole is a prodrug and is selective for anaerobic bacteria due to their ability to intracellularly reduce the nitro group of metronidazole to give nitroso-containing intermediates. These can covalently bind to DNA, disrupting its helical structure, inducing DNA strand breaks and inhibiting bacterial nucleic acid synthesis, ultimately resulting in bacterial cell death.
Esophageal Neoplasms: Tumors or cancer of the ESOPHAGUS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Incidence rates of Barrett's esophagus and adenocarcinoma in each group were evaluated by histological analysis." | 1.43 | Alteration of Esophageal Microbiome by Antibiotic Treatment Does Not Affect Incidence of Rat Esophageal Adenocarcinoma. ( Arakawa, T; Fujiwara, Y; Gi, M; Nagami, Y; Sawada, A; Shiba, M; Tanaka, F; Tanigawa, T; Tominaga, K; Wanibuchi, H; Watanabe, T; Yamagami, H, 2016) |
| "In the patients with esophageal cancer after MZ administration via the gastrostoma, the nature and time course of drug accumulation in the blood was identical, however accumulation maximum was lower and reached 219 +/- 25 micrograms/ml." | 1.27 | [Pharmacokinetics and the effects of metronidazole during its use as a radiosensitizer]. ( Dar'ialova, SL; Kiseleva, ES; Poliakov, PIu; Zel'vin, BM; Zimina, ES, 1984) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 8 (57.14) | 18.7374 |
| 1990's | 2 (14.29) | 18.2507 |
| 2000's | 1 (7.14) | 29.6817 |
| 2010's | 3 (21.43) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lai, MJ | 1 |
| Chiueh, TS | 1 |
| Huang, ZY | 1 |
| Lin, JC | 1 |
| Sawada, A | 1 |
| Fujiwara, Y | 1 |
| Nagami, Y | 1 |
| Tanaka, F | 1 |
| Yamagami, H | 1 |
| Tanigawa, T | 1 |
| Shiba, M | 1 |
| Tominaga, K | 1 |
| Watanabe, T | 1 |
| Gi, M | 1 |
| Wanibuchi, H | 1 |
| Arakawa, T | 1 |
| Hariri, S | 1 |
| Gouin, P | 1 |
| Tuech, JJ | 1 |
| Veber, B | 1 |
| Dureuil, B | 1 |
| Tsyb, AF | 1 |
| Konopliannikov, AG | 1 |
| Kudriavtseva, GT | 1 |
| Goldobenko, GV | 3 |
| Kherkheulidze, ZSh | 1 |
| Shchebetenko, IuE | 1 |
| Polotskiĭ, BE | 1 |
| Kiseleva, ES | 2 |
| Dar'ialova, SL | 2 |
| Zel'vin, BM | 1 |
| Poliakov, PIu | 1 |
| Zimina, ES | 1 |
| Ruol, A | 1 |
| Bertiato, G | 1 |
| Boscarin, S | 1 |
| Cusinato, R | 1 |
| Pascarella, M | 1 |
| Tonin, EA | 1 |
| Santi, S | 1 |
| Ancona, E | 1 |
| Azhigaliev, NA | 1 |
| Kusherbaev, SK | 1 |
| Sadykov, SS | 1 |
| Asanov, AA | 1 |
| Fel'dman, SZ | 1 |
| Tetteroo, GW | 1 |
| Wagenvoort, JH | 1 |
| Castelein, A | 1 |
| Tilanus, HW | 1 |
| Ince, C | 1 |
| Bruining, HA | 1 |
| Isaev, IG | 4 |
| Beibutov, SM | 1 |
| Tkachev, SI | 2 |
| Beĭbutov, ShM | 1 |
2 reviews available for metronidazole and Esophageal Neoplasms
| Article | Year |
|---|---|
[Analysis of clinical experience in the use of metronidazole as a radiosensitizer of tumors].
Topics: Brain Neoplasms; Clinical Trials as Topic; Esophageal Neoplasms; Female; Genital Neoplasms, Female; | 1983 |
[Electron acceptor compounds as radiation sensitizers of hypoxic cells in human tumors].
Topics: Brain Neoplasms; Combined Modality Therapy; Esophageal Neoplasms; Female; Head and Neck Neoplasms; H | 1984 |
3 trials available for metronidazole and Esophageal Neoplasms
| Article | Year |
|---|---|
[Use of electron acceptor compounds in radiotherapy].
Topics: Clinical Trials as Topic; Esophageal Neoplasms; Female; Humans; Laryngeal Neoplasms; Metronidazole; | 1983 |
[Analysis of clinical experience in the use of metronidazole as a radiosensitizer of tumors].
Topics: Brain Neoplasms; Clinical Trials as Topic; Esophageal Neoplasms; Female; Genital Neoplasms, Female; | 1983 |
Selective decontamination to reduce gram-negative colonisation and infections after oesophageal resection.
Topics: Adult; Aged; Cefotaxime; Chi-Square Distribution; Cross Infection; Drug Administration Schedule; Dru | 1990 |
10 other studies available for metronidazole and Esophageal Neoplasms
| Article | Year |
|---|---|
The first Clostridium difficile ribotype 027 strain isolated in Taiwan.
Topics: Aged; Anti-Bacterial Agents; Carcinoma, Squamous Cell; Chemoradiotherapy; Clostridioides difficile; | 2016 |
Alteration of Esophageal Microbiome by Antibiotic Treatment Does Not Affect Incidence of Rat Esophageal Adenocarcinoma.
Topics: Adenocarcinoma; Ampicillin; Anastomosis, Surgical; Animals; Anti-Bacterial Agents; Barrett Esophagus | 2016 |
Clostridium difficile infection causing multiple organ failure and small-bowel enteritis.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Clostridioides difficile; Clostridium Infections; Drug | 2011 |
[Pharmacokinetics and the effects of metronidazole during its use as a radiosensitizer].
Topics: Adult; Esophageal Neoplasms; Humans; Inactivation, Metabolic; Intestinal Absorption; Kidney; Kidney | 1984 |
Short-Term prophylaxis with ceftriaxone plus metronidazole in esophageal cancer surgery.
Topics: Adult; Aged; Aged, 80 and over; Antibiotic Prophylaxis; Bacteriuria; Ceftriaxone; Drug Administratio | 2000 |
[Results of radiation and chemoradiation therapy in esophageal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Combined Modality Therapy; Dactinomycin; | 1990 |
[Radiation therapy of esophageal carcinoma using dynamic dose fractionation in combination with metronidazole and local hyperthermia].
Topics: Chemical Fractionation; Combined Modality Therapy; Dose-Response Relationship, Radiation; Esophageal | 1988 |
[The prognostic significance of the rate of growth in the radiation treatment of esophageal cancer].
Topics: Combined Modality Therapy; Esophageal Neoplasms; Humans; Hyperthermia, Induced; Metronidazole; Neopl | 1989 |
[Prognosis and results of radiotherapy of esophageal cancer with the use of radiomodifiers].
Topics: Carcinoma, Squamous Cell; Combined Modality Therapy; Esophageal Neoplasms; Female; Humans; Hyperther | 1989 |
[Radiotherapy of esophageal cancer using local hyperthermia and metronidazole (polyradiomodification)].
Topics: Carcinoma, Squamous Cell; Combined Modality Therapy; Esophageal Neoplasms; Female; Humans; Hyperther | 1986 |